Jo Nash

Almost half of all private equity firms in a new survey expect litigation to increase in the next two years. But the major threat is unlikely to come from regulators, as most firms seem to think.

Many FTSE 100 chief executives are considering a move into private equity, either as operating partners, advisers or individual investors, despite misgivings about the industry’s short-termism and excessive leverage.

Leading law firm Linklaters has hired Brian Gray from rival law firm Freshfields Bruckhaus Deringer, as it looks to strengthen its offering to private equity clients.

New York-based news aggregation site Daylife has raised $8 million from two UK venture capital firms, in the latest example of US start-ups taking funding from VCs based in London rather than Silicon Valley.

Many FTSE 100 chief executives are considering a move into private equity, either as operating partners, advisers or individual investors, despite misgivings about the industry’s short-termism and excessive leverage.

Kiadis Pharma, the biotech company backed by European venture capital firm Esprit Capital Partners, has raised €15 million in its latest funding round.

Leading law firm Linklaters has hired Brian Gray from rival law firm Freshfields Bruckhaus Deringer, as it looks to strengthen its offering to private equity clients.

New York-based news aggregation site Daylife has raised $8 million from two UK venture capital firms, in the latest example of US start-ups taking funding from VCs based in London rather than Silicon Valley.

London-based Advent Venture Partners has expanded its life sciences team with the recruitment of two new partners – both former biotech entrepreneurs.

Many FTSE 100 chief executives are considering a move into private equity, either as operating partners, advisers or individual investors, despite misgivings about the industry’s short-termism and excessive leverage.